Clarity Pharmaceuticals Ltd (CU6) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) has a cash flow conversion efficiency ratio of -0.205x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-47.79 Million ≈ $-33.82 Million USD) by net assets (AU$232.81 Million ≈ $164.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CU6 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Clarity Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Clarity Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Clarity Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clarity Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Forus S.A
SN:FORUS
|
0.135x |
|
Innova Captab Limited
NSE:INNOVACAP
|
0.027x |
|
Jiangsu Jiangnan High Polymer Fiber Co Ltd
SHG:600527
|
0.001x |
|
Shandong Shuangyi Technology Co Ltd
SHE:300690
|
0.025x |
|
Amotiv Limited
TO:AOV
|
0.090x |
|
Jiangsu Liba Enterprise Joint-Stock Co Ltd
SHG:603519
|
0.051x |
|
N-Able Inc
NYSE:NABL
|
0.022x |
|
Shenzhen Guangju Energy Co Ltd
SHE:000096
|
0.003x |
Annual Cash Flow Conversion Efficiency for Clarity Pharmaceuticals Ltd (2018–2025)
The table below shows the annual cash flow conversion efficiency of Clarity Pharmaceuticals Ltd from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Clarity Pharmaceuticals Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$90.23 Million ≈ $63.84 Million |
AU$-54.77 Million ≈ $-38.75 Million |
-0.607x | -105.38% |
| 2024-06-30 | AU$146.30 Million ≈ $103.51 Million |
AU$-43.24 Million ≈ $-30.59 Million |
-0.296x | +25.66% |
| 2023-06-30 | AU$69.18 Million ≈ $48.95 Million |
AU$-27.50 Million ≈ $-19.46 Million |
-0.398x | -175.41% |
| 2022-06-30 | AU$92.24 Million ≈ $65.26 Million |
AU$-13.31 Million ≈ $-9.42 Million |
-0.144x | +61.87% |
| 2021-06-30 | AU$20.28 Million ≈ $14.35 Million |
AU$-7.68 Million ≈ $-5.43 Million |
-0.379x | +54.78% |
| 2020-06-30 | AU$8.16 Million ≈ $5.77 Million |
AU$-6.83 Million ≈ $-4.83 Million |
-0.837x | -108.35% |
| 2019-06-30 | AU$9.23 Million ≈ $6.53 Million |
AU$-3.71 Million ≈ $-2.62 Million |
-0.402x | +48.30% |
| 2018-06-30 | AU$1.93 Million ≈ $1.37 Million |
AU$-1.50 Million ≈ $-1.06 Million |
-0.777x | -- |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic ra… Read more